The estimated Net Worth of Alan M Garber is at least $27.7 Million dollars as of 21 March 2024. Alan Garber owns over 23,491 units of Vertex Pharmaceuticals stock worth over $26,067,024 and over the last 20 years he sold VRTX stock worth over $1,144,581. In addition, he makes $518,782 as Independent Director at Vertex Pharmaceuticals.
Sign up
Alan Garber VRTX stock SEC Form 4 insiders trading
Alan has made over 12 trades of the Vertex Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 23,491 units of VRTX stock worth $459,719 on 21 March 2024.
The largest trade he's ever made was exercising 86,956 units of Vertex Pharmaceuticals stock on 7 January 2020 worth over $468,693. On average, Alan trades about 8,579 units every 63 days since 2005. As of 21 March 2024 he still owns at least 54,908 units of Vertex Pharmaceuticals stock.
You can see the complete history of Alan Garber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alan Garber biography
Dr. Alan Garber, M.D. Ph.D., is Independent Director of the Company. Dr. Garber is Provost of Harvard University and the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, Professor of Public Policy in the Harvard Kennedy School of Government, and Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health. From 1998 until he joined Harvard in 2011, he was the Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. Dr. Garber is a member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and the American Academy for Arts and Sciences. He is a Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Royal College of Physicians. Dr. Garber is also a Research Associate with the National Bureau of Economic Research and served as founding Director of its Health Care Program for nineteen years. He also has served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services. Dr. Garber has been a member of the Board of Directors of Exelixis, Inc., a biopharmaceutical company, since 2005. Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. with research honors from Stanford University.
What is the salary of Alan Garber?
As the Independent Director of Vertex Pharmaceuticals, the total compensation of Alan Garber at Vertex Pharmaceuticals is $518,782. There are 19 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
How old is Alan Garber?
Alan Garber is 63, he's been the Independent Director of Vertex Pharmaceuticals since 2017. There are 4 older and 20 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
What's Alan Garber's mailing address?
Alan's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at Vertex Pharmaceuticals
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
What does Vertex Pharmaceuticals's logo look like?
Complete history of Alan Garber stock trades at Exelixis Inc and Vertex Pharmaceuticals
Vertex Pharmaceuticals executives and stock owners
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jeffrey Leiden,
Executive Chairman of the Board -
Stuart Arbuckle,
Executive Vice President, Chief Commercial Officer -
Reshma Kewalramani,
President, Chief Executive Officer, Director -
Amit Sachdev,
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO -
David Altshuler,
Executive Vice President - Global Research, Chief Scientific Officer -
Michael Parini,
Executive Vice President, Chief Legal and Administrative Officer -
Dr. Reshma Kewalramani FASN, M.D.,
CEO, Pres & Director -
Charles Wagner,
Chief Financial Officer, Executive Vice President -
Paul Silva,
Senior Vice President, Controller -
Dr. Jeffrey Marc Leiden M.D., Ph.D.,
Exec. Chairman -
Stuart A. Arbuckle B.Sc.,
Exec. VP & COO -
Dr. David M. Altshuler,
Exec. VP of Global Research & Chief Scientific Officer -
Charles F. Wagner Jr.,
Exec. VP & CFO -
Bruce Sachs,
Co-Lead Independent Director -
Margaret McGlynn,
Independent Director -
Terrence Kearney,
Independent Director -
Sangeeta Bhatia,
Independent Director -
Yuchun Lee,
Independent Director -
William Young,
Independent Director -
Alan Garber,
Independent Director -
lloyd Carney,
Independent Director -
Michael Partridge,
Vice President - Investor Relations -
Diana McKenzie,
Independent Director -
Nia Tatsis,
Senior Vice President, Chief Regulatory Officer -
John Gray,
Senior Vice President, Genetic Therapies -
Gerald Bruce,
Executive Vice President, Commercial Operations -
Carmen Bozic,
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer -
Joy Liu,
Sr. VP & Gen. Counsel -
Damian W. Wilmot Esq.,
Sr. VP, Chief Risk and Compliance Officer -
Mike Tirozzi,
SVP and Chief Information & Data Officer -
Kristen Ambrose,
Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services -
Joshua S Boger,
Chairman & CEO -
Elaine Ullian,
Director -
Ian F Smith,
SVP & CFO -
Jeffrey Chodakewitz,
SVP GMDA, CMO -
Thomas Graney,
Chief Financial Officer -
Michel Lagarde,
Director -
Wayne Joseph Riley,
Director -
Peter Mueller,
CSO & SVP Drug Discovery -
Thomas Connolly,
SVP, Human Resources -
Kenneth L Horton,
EVP & Chief Legal Officer -
Megan E Pace,
SVP, Corp. Communications -
Christiana Stamoulis,
SVP, Corp Strategy & Bus Devlp -
Matthew Emmens,
Director -
Lisa Kelly,
SVP, Human Resources -
Dennis L Winger,
Director -
Eugene Cordes,
Director -
Nancy Wysenski,
EVP & Chief Commercial Officer -
David T Howton,
SVP -
Kenneth S Boger,
SVP & General Counsel -
Kurt Graves,
EVP, Chief Commercial Officer -
John J Alam,
SVP, Drug Eval. & Appr. -
Stuart J Collinson,
Director -
Charles A Sanders,
Director -
Roger W Brimblecombe,
Director -
Freda C Lewis Hall,
EVP, Medicines Development -
Eve Elizabeth Slater,
Director -
Richard C Garrison,
SVP, Organizational Developmen -
Johanna Messina Power,
Controller -
Victor A Hartmann,
EVP, Strategic & Corp. Devlp. -
Eric Brandt,
Director -
Lynne H Brum,
VP, Corp. Comm.&Financial Plan -
Paul A Negulescu,
VP, Research -
John F Niblack,
Director -
Iain P M Buchanan,
VP, European Operations -
Vicki L Sato,
President -
N Anthony Coles,
SVP, Comm. Ops. -
Bastiano Sanna,
EVP, Cell & Genetic Therapies -
Joy Liu,
SVP, General Counsel -
Kristen Ambrose,
SVP & Chief Accounting Officer -
Suketu Upadhyay,
Director -
Jonathan Biller,
EVP and Chief Legal Officer -
Nancy Thornberry,
Director -
Edward Morrow Iii Atkinson,
EVP, Chief Technical Ops. Off. -
Jennifer Schneider,
Director